0001628280-24-009083.txt : 20240305
0001628280-24-009083.hdr.sgml : 20240305
20240305175525
ACCESSION NUMBER: 0001628280-24-009083
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SACCARO JAMES
CENTRAL INDEX KEY: 0001593636
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41528
FILM NUMBER: 24722858
MAIL ADDRESS:
STREET 1: ONE BAXTER PARKWAY
CITY: DEERFIELD
STATE: IL
ZIP: 60015
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GE HealthCare Technologies Inc.
CENTRAL INDEX KEY: 0001932393
STANDARD INDUSTRIAL CLASSIFICATION: X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 882515116
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 WEST MONROE STREET
CITY: CHICAGO
STATE: IL
ZIP: 60661
BUSINESS PHONE: 833-735-1139
MAIL ADDRESS:
STREET 1: 500 WEST MONROE STREET
CITY: CHICAGO
STATE: IL
ZIP: 60661
FORMER COMPANY:
FORMER CONFORMED NAME: GE Healthcare Holding LLC
DATE OF NAME CHANGE: 20220603
4
1
wk-form4_1709679314.xml
FORM 4
X0508
4
2024-03-01
0
0001932393
GE HealthCare Technologies Inc.
GEHC
0001593636
SACCARO JAMES
500 W. MONROE STREET
CHICAGO
IL
60661
0
1
0
0
Chief Financial Officer
0
Common Stock, par value $0.01 per share
2024-03-01
4
A
0
10245
0
A
71938
D
Employee Stock Option (right to buy)
92.72
2024-03-01
4
A
0
29141
0
A
2034-03-01
Common Stock, par value $0.01 per share
29141
29141
D
Award of restricted stock units with respect to GE HealthCare Technologies Inc. ("GE HealthCare") common stock, of which 33% will vest on September 1, 2025, 33% will vest on September 1, 2026, and 34% will vest on September 1, 2027, subject to certain conditions.
Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare common stock.
Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 1, 2025, 33% will become exercisable on September 1, 2026, and 34% will become exercisable on September 1, 2027, subject to certain conditions.
/s/ Frank R. Jimenez, General Counsel and Corporate Secretary, as attorney-in-fact
2024-03-05